Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) have been assigned an average rating of “Buy” from the seven analysts that are presently covering the stock, MarketBeat reports. Four equities research analysts have rated the stock with a buy rating and three have issued a strong buy rating on the company.

Several research analysts have commented on BAYRY shares. JPMorgan Chase & Co. raised shares of Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research note on Monday, December 8th. Barclays upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Tuesday, January 6th. Morgan Stanley upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Wednesday, December 3rd. Finally, Zacks Research raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 20th.

Key Bayer Aktiengesellschaft News

Here are the key news stories impacting Bayer Aktiengesellschaft this week:

• Positive Sentiment: The proposed settlement (announced as about $7.25B) could materially reduce future litigation overhang and provide greater legal certainty for the company’s U.S. business, which some investors view as a constructive step. Bayer Proposes New $7 Billion Plan to Settle Roundup Litigation
• Positive Sentiment: Bayer’s CEO framed the deal as a complement to its Supreme Court appeal strategy, suggesting management aims to neutralize future claims while pursuing broader legal relief — a legal‑strategy rationale some investors could welcome. Bayer CEO says Roundup settlement is important addition to Supreme Court case
• Neutral Sentiment: Clinical pipeline news: Bayer updated the DARO‑DUB real‑world study for darolutamide in advanced prostate cancer — a development for the pharma franchise but unlikely to offset financial/legal headlines in the near term. Bayer’s DARO-DUB Study Sets Up New Real-World Test for Darolutamide
• Neutral Sentiment: Technical/short‑term trading: the stock showed intraday volatility (one note flagged a prior session surge on above‑average volume), but analysts say recent earnings‑estimate revisions do not support clear upside momentum. Bayer (BAYRY) Surges 6.0%: Is This an Indication of Further Gains?
• Negative Sentiment: Large cash/charge risk: headlines cite a $7.25B proposed class settlement and separate reports of up to $10.5B in potential liabilities — the scale of the payout could meaningfully affect cash, leverage and future capital allocation, pressuring sentiment. Bayer agrees to $7.25 billion proposed settlement over thousands of Roundup cancer lawsuits
• Negative Sentiment: Market reaction: multiple outlets report the stock slumped after the settlement announcement and amid uncertainty over the final size and structure of any deal; that negative sentiment drove the recent pullback. Bayer shares make this surprising move after $7.25 billion Roundup settlement accord

Bayer Aktiengesellschaft Price Performance

Shares of OTCMKTS:BAYRY opened at $13.31 on Monday. Bayer Aktiengesellschaft has a 12 month low of $5.30 and a 12 month high of $14.85. The company has a current ratio of 1.14, a quick ratio of 0.71 and a debt-to-equity ratio of 1.10. The stock has a market cap of $52.31 billion, a P/E ratio of -147.87, a P/E/G ratio of 5.17 and a beta of 0.68. The company has a 50 day moving average of $12.08 and a 200 day moving average of $9.56.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.